Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative immune regulator. Heterozygous CTLA4 germline mutations can cause a complex immune dysregulation syndrome in human subjects. Objective: We sought to characterize the penetrance, clinical features, and best treatment options in 133 CTLA4 mutation carriers. Methods: Genetics, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers. Results: We identified 133 subjects from 54 unrelated families carrying 45 different heterozygous CTLA4 mutations, including 28 previously undescribed mutations. Ninety mutation carriers were considered affected, suggesting a clinical penetrance of at least 67%; median age of onset was 11 years, and the mortality rate within affected mutation carriers was 16% (n 5 15). Main clinical manifestations included hypogammaglobulinemia (84%), lymphoproliferation (73%), autoimmune cytopenia (62%), and respiratory (68%), gastrointestinal (59%), or neurological features (29%). Eight affected mutation carriers had lymphoma, and 3 had gastric cancer. An EBV association was found in 6 patients with malignancies. CTLA4 mutations were associated with lymphopenia and decreased T-, B-, and natural killer (NK) cell counts. Successful targeted therapies included application of CTLA-4 fusion proteins, mechanistic target of rapamycin inhibitors, and hematopoietic stem cell transplantation. EBV reactivation occurred in 2 affected mutation carriers after immunosuppression. Conclusions: Affected mutation carriers with CTLA-4 insufficiency can present in any medical specialty. Family members should be counseled because disease manifestation can occur as late as 50 years of age. EBV-and cytomegalovirusassociated complications must be closely monitored. Treatment interventions should be coordinated in clinical trials. Heterozygous germline mutations in cytotoxic T-lymphocyte antigen 4 (CTLA4) can lead to haploinsufficiency, impaired CTLA-4 dimerization, or impaired ligand binding and can cause an autosomal dominant immune dysregulation syndrome and immunodeficiency in human subjects. [1] [2] [3] CTLA-4 is a negative immune regulator essential for the function of regulatory T (Treg) cells, which are responsible for maintaining self-tolerance and immune homeostasis through suppression of T-cell proliferation and differentiation. [4] [5] [6] [7] [8] [9] CTLA-4 competes with the costimulatory receptor CD28 for its ligands CD80 and CD86, which are expressed on antigen-presenting cells (APCs). 10, 11 CTLA-4 binds these ligands with a higher affinity and avidity than CD28 and removes them from the surfaces of APCs through transendocytosis, resulting in reduction in APC-mediated activation of conventional T cells. 12, 13 CTLA4 encodes for 4 exons: exon 1 encodes the signal peptide, exon 2 encodes the ligand-binding and dimerization domains, exon 3 encodes the transmembrane domain, and exon 4 encodes the cytoplasmic tail. 14 The clinical diagnosis of CTLA-4 insufficiency is complicated by a highly variable phenotype, including various organ-specific autoimmune diseases, hypogammaglobulinemia, recurrent infections, and malignancies; the natural history of this condition is largely unknown. 1, 3, [15] [16] [17] [18] [19] CTLA-4 insufficiency in human subjects was associated with incomplete penetrance.
Here we describe the largest known cohort of CTLA4 mutation carriers, including 133 subjects, to aid diagnosis in similar cases and provide guidance for their treatment.
METHODS
For information on the materials and methods used in this study, please see the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS

Age distribution and origin
We identified 133 subjects of 54 unrelated families (66 female and 67 male subjects) from Europe (n 5 87), Asia (n 5 26), South America (n 5 7), and North America (n 5 13, Fig 1 and Table I) . 2, 3, [15] [16] [17] [18] [19] Median age of onset was 11 years (<1-59 years), and median age at evaluation was 23 years in affected mutation carriers and 46 years in unaffected carriers (Fig 2) . Three-fourths of affected mutation carriers were less than 18 years of age when showing first symptoms; there was no significant difference in age of onset between women and men.
Genetics and protein function
We identified 45 unique heterozygous CTLA4 germline mutations, including 28 missense mutations, 10 deletions or insertions, and 7 nonsense mutations (Fig 3 and Table I ). Mutations in 7 affected carriers occurred de novo. Twenty-eight mutations were novel, and 17 have been described previously. [1] [2] [3] [15] [16] [17] [18] [19] Eight mutations were located in exon 1, 31 in exon 2, and 6 in exon 3. Mutations at 7 loci were identified in multiple families (Table II) . CTLA-4 expression within stimulated Treg cells was reduced in all tested CTLA4 mutation carriers. CD4
1 T cells were cocultured with CD80-green fluorescent protein-expressing CHO cells, and green fluorescent protein uptake was measured within CTLA-4 1 cells to estimate the ability of cells to perform transendocytosis, which was reduced in all tested mutation carriers (Table I and see Fig E1 in this article's Online Repository at www.jacionline.org). 13 An association between genotype and onset, penetrance, or disease phenotype was not observed. Thus far, 115 exonic variants have been described within CTLA4; all but 2 variants have a minor allele frequency of less than 0.01, and 7 variants have been described to be disease causing or are part of our cohort (see Table E2 in this article's Online Repository at www.jacionline.org).
1,2,19
Symptoms and signs at presentation First symptoms included autoimmune cytopenia (33%), respiratory manifestations (21%), enteropathy (17%), type 1 diabetes (8%), neurological symptoms (seizures, headache, and nausea; 6%), thyroid disease (5%), arthritis (3%), growth retardation, fever or night sweats, atopic dermatitis, alopecia (2% each), and primary biliary cirrhosis, Addison disease, or a wound-healing disorder in 1 affected mutation carrier each.
Main diagnoses
At the time of data collection, affected mutation carriers had diverse main diagnoses: 26 (29%) had a diagnosis of cytopenia, and 23 (26%) had common variable immunodeficiency (CVID). CVID was diagnosed according to the revised European Society for Immune Deficiencies registry. 20, 21 Twenty (22%) affected mutation carriers had mainly severe gastrointestinal symptoms, such as enteropathy or inflammatory bowel disease, and 10 (11%) had respiratory disease, including infections (n 5 9), granulomatous lymphoproliferative interstitial lung disease (GLILD; n 5 9), bronchiectasis (n 5 9), and asthma (n 5 2). In 7 (8%) affected mutation carriers, lymphoma was the leading diagnosis, 5 (6%) had mainly endocrinopathies, and 4 (4%) had inflammatory central nervous system disease. Individual affected mutation carriers had widespread lymphadenopathy (n 5 Table E1 in this article's Online Repository at www.jacionline.org). At the time of data collection, 65 affected mutation carriers were undergoing immunosuppression. Fortythree mutation carriers were considered unaffected (see Table E1 ).
Clinical spectrum of CTLA-4 insufficiency
Although CTLA4 mutations were associated with autoimmunity and immune dysregulation in all affected mutation carriers, the affected organ systems varied substantially: hypogammaglobulinemia (84%), lymphoproliferation (73%), respiratory involvement (68%), gastrointestinal features (59%), autoimmune cytopenia (62%), dermatologic involvement (56%, mainly atopic dermatitis), endocrinopathy (33%), and neurological features (29%) were often observed. Arthritis (14%), growth retardation (14%), and renal (12%) or liver (12%) involvement were less frequent (Fig 4 and see Table E1 ). One affected mutation carrier had severe psoriatic arthritis (T.II.1). In total, 90 (67.6%) of the 133 CTLA4 mutation carriers were considered affected because they had sought medical attention for disease-related symptoms. Case reports can be found in the Case vignettes section in this article's Online Repository.
Nonmalignant lymphoproliferation
Sixty-two (73%) affected mutation carriers had nonmalignant lymphoproliferation, including splenomegaly (n 5 51, Figs 3 and 5, A), chronic lymphadenopathy (n 5 43), and hepatomegaly (n 5 17). Thirteen affected mutation carriers underwent splenectomy for severe cytopenia. Forty-three (50%) affected mutation carriers had lymphocytic infiltration into the lung (n 5 27), gastrointestinal tract (n 5 17), brain (n 5 12), bone marrow (n 5 6; Fig 6, E) , kidney (n 5 6), or retroperitoneal tissue (n 5 4). On biopsy, 21 affected mutation carriers had T-cell infiltrations; both CD4 1 (n 5 9) and CD8 1 (n 5 8) infiltrations were observed. Twelve had predominately B-cell infiltrations, 4 of them in the lung tissue as part of their GLILD. Ten of 29 affected mutation carriers with nonmalignant lymphoproliferation undergoing biopsy also had granulomas in at least 2 different organ systems on biopsy: 8 in the lung, 2 in the lymph nodes, and 1 each in the kidney, brain, or gastrointestinal tract. Pedigrees of all families with more than 1 CTLA4 mutation carrier. Squares, Male subjects; circles, female subjects; solid symbols, mutation carriers classified as affected; gray symbols, mutation carriers classified as unaffected; slashed symbols, deceased subjects. *CTLA4 sequencing was performed. §Genotype inferred from clinical symptoms. 
Respiratory tract involvement
Pathogens and infections
Sixty-one percent (55/90) of affected mutation carriers had respiratory tract infections, including pneumonia, sinusitis, and otitis media. Isolated pathogens were Haemophilus influenzae (n 5 6) and Streptococcus pneumoniae (n 5 4). The most common enteritis pathogen was Salmonella enterica serotype enteritidis (6/7). Staphylococcus aureus was detected in various organs of 11 affected mutation carriers. Twenty-seven affected mutation carriers reactivated a herpesvirus infection: EBV led to clinically apparent infections in 16 affected mutation carriers (Fig 6, C) , including EBV-induced hemophagocytic lymphohistiocytosis (HLH) (B.II.3). Two affected mutation carriers had EBV-associated lymphoid granulomatosis in the lung or brain (H.II.2 and N.III.2). Cytomegalovirus (CMV) reactivation was found in 9 affected mutation carriers, including CMVassociated diarrhea or gastritis (D.II.1, M.II.3, and NN.II.1), chronic active CMV infection (LL.II.1), CMV lymphadenitis (K.II.1), bilateral parotid hypertrophy (O.II.1), and respiratory CMV infection (R.II.5); 8 of these patients were receiving immunosuppressive treatment. Mycobacterium tuberculosis PCR results were positive in 4 affected mutation carriers, with 2 of them having pulmonary or esophageal tuberculosis (A.II.8 and A.II.9).
Fungal infections were present in 15 affected mutation carriers with either Candida species pluralis infections (n 5 13) or Aspergillus species pluralis pneumonia (n 5 2); 13 of them received immunosuppressive treatment at the time of data collection. Ten affected mutation carriers, 8 of whom were immunosuppressed, had sepsis caused by bacterial or fungal pathogens, leading to death in 5. In 1 affected mutation carrier sepsis followed perforation of the small bowel, and in 1 Salmonella enterica serotype enteritidis sepsis was the first manifestation of CTLA-4 insufficiency at the age of 3 months (UU.IV.12).
Gastrointestinal involvement
Gastrointestinal involvement across our cohort was frequent (59% [53/90]) and often severe. Nine of the 15 deceased affected mutation carriers had severe gastrointestinal features before death. Diarrhea was frequent (n 5 51), ranging from mild to severe, with weight loss, wasting, and total parenteral nutrition dependency. Pathogens were identified rarely. Crohn disease (n 5 7), atrophic gastritis (n 5 8; Fig 6, #Disease-causing effect of the mutation is functionally proved by using a transendocytosis assay (Fig E2) . **P1 and P2 with chromosome 2 contiguous gene deletion involving CTLA4 are not included within all calculations of the clinical spectrum.
ulcerative lesions or deep-seated inflammatory changes, as seen in patients with severe Crohn disease. Despite decreased serum immunoglobulin levels, histology revealed increased numbers of plasma cells in the gastric (B.II.4 and QQ.II.1), intestinal, and colonic (QQ.II.1) lamina propria. Further histologic changes included severe lymphocytic infiltrates and EBV-positive gastric cancer (Fig 6, C) . Median age of onset of gastrointestinal features was 15 years (<1-51 years).
Cytopenia
Autoimmune cytopenia was often severe, life-threatening, and treatment resistant and was the main indication for allogeneic hematopoietic stem cell transplantation (alloHSCT; 7/12).
Sixty-two percent (55/89) of affected mutation carriers had autoimmune cytopenia, including immune thrombocytopenia (n 5 41), autoimmune hemolytic anemia (n 5 37), pure red cell aplasia (n 5 2), or autoimmune neutropenia (n 5 16). In 32 affected mutation carriers cytopenia affected more than 1 cell lineage; 19 of these carriers were given a diagnosis of Evans syndrome, and 9 had a trilineage cytopenia. Median age of onset of cytopenia was 12 years (1.3-48 years).
Neurological involvement
Twenty-eight percent (28/90) of affected mutation carriers presented with a broad spectrum of neurological features (Fig 5, F-H, and Fig 6, F) . Three had autoimmune encephalitis or encephalomyelitis with cerebral perivascular lymphocytic infiltrations leading to vomiting, headache, or paraplegia with bladder dysfunction (N.III.2, P.II.2, and GG.II.1). In 4 affected mutation carriers neurological features were attributed to cerebral infiltrations that did not undergo biopsy: nausea and headache (A.III.1), facial nerve paralysis (H.II.1), aphasia and paresis of the left arm (K.II.1), or a patchy inflammatory demyelinating process with twitching episodes of hands with normal electroencephalography (WW.II.1). Three affected mutation carriers had neurological features secondary to hematologic causes: hemiplegia after brain ischemia during autoimmune hemolytic anemia (DD.II.1), hemiparesis and aphasia caused by cerebral arterial thrombosis (H.II.2), and hemiparesis after cerebral bleeding caused by thrombocytopenia (GG.II.1). In 2 affected mutation carriers clinical and radiologic investigation could not identify an underlying cause for tonic-clonic seizures or recurrent transient paralysis of the left leg, respectively (A.II.8 and EE.II.1). One affected mutation carrier had life-threatening HLH with increased cerebral pressure, leading to cerebral herniation and seizures (J.II.1). Other diagnoses were stiff person syndrome (H.I.2), West syndrome and developmental delay (UU.V.1), progressive memory loss starting at age 57 years (UU.III.7), and chronic hydrocephalus (UU.III.4). Two affected mutation carriers had optic neuritis (TT.II.4) and retinal tear caused by lymphocytic infiltrations into the retina (SS.II.1). One had gliosis (ZZ.II.1), and 1 had cognitive dysfunction, chorea, ataxia, and mood instability; biopsies revealed inflammation, lymphocytic infiltrations, and a demyelinating-like transformation, which was clinically responsive to steroid treatment (G.III.1). One affected mutation carrier was given a diagnosis of tuberous sclerosis with tonic-clonic seizures, right-sided hemiparesis, mental retardation, angiofibromas, angiomyolipomas, and a concurrent TSCA2 mutation (LL.II.1).
Malignancies
Eleven (12%) affected mutation carriers had malignancies. Of 8 with lymphoma, EBV positivity was found in 5. Lymphoma in 5 affected mutation carriers was classified as Hodgkin lymphoma; 1 had relapsing EBV-associated diffuse large B-cell lymphoma (K.II.1) and 1 had Burkitt lymphoma (FF. II.1; Fig 6, G and H) . Four affected mutation carriers died of complications of their lymphoma, and 2 underwent successful alloHSCT.
Three affected mutation carriers had gastric adenocarcinoma, including 1 with EBV-associated carcinoma (B.II.4; Fig 6, C) and 1 with CMV-associated carcinoma (M.II.3). Two affected mutation carriers subsequently underwent total gastrectomy, one of whom died after bacterial sepsis (M.II.3), whereas the other is alive and well (G.III.2). Another had severe enteropathy and cytopenia and died after colectomy (F.II.1). Three affected mutation carriers died after alloHSCT because of graft-versus-host disease (Q.II.1 and LL.II.1) or diabetic ketoacidosis (S.II.1). There was a significant difference in age of death between affected and unaffected CTLA4 mutation carriers (Fig 2, B) .
Immunologic phenotype
Thirty-nine percent (26/66) of affected mutation carriers with available immunologic data had lymphopenia, 24 of whom were receiving immunosuppressive treatment at the time of data collection. The absolute CD3
1 T-cell count was reduced in 36% (16/44) of affected mutation carriers. The absolute CD3
1 CD4
1
T cell count was reduced in 20% (13/62) of affected mutation 
FoxP3
1 Treg cells was increased significantly in mutation carriers in comparison with that in healthy control subjects (P 5 .0034). There was no significant difference in Treg cell percentages between affected and unaffected mutation carriers (P 5 .3882). Eight mutation carriers had Treg cell numbers greater than the normal range. Absolute CD3
1
CD8
1 cytotoxic T-cell counts were normal in 60% (35/58) of affected mutation carriers. Double-negative T-cell counts were increased up to 5.3% (median, 2.2%; normal value, 0.3% to 2.0%) in 53% of tested affected mutation carriers (9/17). Absolute CD19 1 B-cell counts were reduced in 41% (26/58) of affected mutation carriers. B-cell subsets showed a decrease in numbers of switched memory B cells (23/30) and, consecutively, a relative increase in numbers of naive B cells (14/29) . CD21 low B-cell counts were increased in all affected mutation carriers tested. Five affected mutation carriers with no history of rituximab therapy had no measurable B cells. Hypogammaglobulinemia was present in 84% (65/77), with low IgM level in 30, low IgG level in 42, and low IgA levels in 53 affected mutation carriers (Fig 4) . Absolute CD16
1
CD56
1 NK cell counts were reduced in 52% (32/61). The percentage of CD3 1 and CD3
1
CD4
1 cells was increased in the majority of affected mutation carriers because the overall lymphopenia affected CD3 Sirolimus led to reduced spleen size (volume decreased from 5 liters to 2.8l) in 1 affected mutation carrier who had arthritis and erythema nodosum during the treatment (E.II.3). In 2 affected mutation carriers sirolimus treatment was discontinued because J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 of ineffectiveness for cytopenia (GG.II.1) or because of increased blood pressure on the background of a renal impairment (B.II.4). In 1 affected mutation carrier CMV copies increased under sirolimus treatment in combination with methylprednisolone (DD.II.1), in 1 lymphopenia worsened (O.II.1), 1 died of sepsis during sirolimus treatment (G.III.1), and in 1 sirolimus treatment was stopped because of serious respiratory tract infections (SS.II.1). Daily dosage ranged from 2 to 2.64 mg (n 5 5); trough levels were available for 2 affected mutation carriers (6.2 and 8 ng/mL), and target blood values were available for 3 affected mutation carriers (8-12 ng/mL, n 5 2; 12-15 ng/mL, n 5 1). Hematopoietic stem cell transplantation. Twelve affected mutation carriers underwent alloHSCT between 10 and 50 years of age. 15 Main indications for transplantation Table E3 in this article's Online Repository at www.jacionline.org). In half of the affected mutation carriers (6/12), the CTLA4 mutation was known before transplantation, the other half underwent transplantation because of the severity of their symptoms, and the CTLA4 mutation was only identified after transplantation.
Immunoglobulin substitution. Sixty-three percent (5/88) of affected mutation carriers received immunoglobulin substitution because of either hypogammaglobulinemia or cytopenia. Twenty-eight affected mutation carriers had both diagnoses at the time of data collection and received immunoglobulin substitution because of both.
Additional treatment options can be found in the Additional treatment options section in this article's Online Repository.
Chromosome 2 contiguous gene deletion involving CTLA4
Two unrelated subjects have a heterozygous 2q33.2-2q33.3 deletion involving CTLA4 and present with a CTLA-4 insufficiency-like phenotype, which is possibly influenced by deletion of additional genes, including CD28 and ICOS (see the Chromosome 2 contiguous gene deletion involving CTLA4 section in this article's Online Repository).
Mutation carriers who did not seek medical attention
We identified 43 unaffected family members carrying the same CTLA4 mutation as their affected relatives. The treating physician of the affected mutation carrier classified family members as unaffected if they did not repeatedly seek medical care, were not undergoing a long-term drug regimen for CTLA-4 insufficiency-related symptoms, or were not restricted in their health-related quality of life because of their symptoms. Their median age at evaluation was 46 years (6-87 years), and therefore in most cases they were beyond the median age of manifestation. On thorough questioning and clinical investigation, 7 carriers had diarrhea without weight loss, 2 had atrophic gastritis or pernicious anemia, and 1 had celiac disease. Three carriers had respiratory tract infections, and in 1 carrier clinically unapparent pulmonary nodules were detected on a routine scan. Nine had dermatologic involvement (psoriasis, eczema, and vitiligo), and 2 had hypothyroidism. One carrier had colon cancer at age 78 years, which was treated successfully with surgery, but the carrier is otherwise healthy at 87 years of age (A.I.2). Four carriers (without recurrent infections) had IgA deficiency; 1 each had low IgG or IgM levels, and 1 had low IgA and IgM levels, possibly contributing to respiratory tract infections (R.III.1). Twenty-six carriers were reported to be completely healthy clinically.
Immunologic phenotyping revealed similarities to affected mutation carriers, including a decrease in NK and CD19
1 B-cell counts but also differences, including significantly greater CD4 1 T-cell counts and a greater percentage of switched memory B cells. There was no significant difference with regard to Treg cell percentages in affected mutation carriers (see Fig E2) . (Fig 6, G) or CD30 immunohistochemistry (red staining in Fig 6, H) . Nuclei of Hodgkin cells and Reed-Sternberg cells were positive for EBER (dark blue staining in inlet of Fig 6, H) .
DISCUSSION
In our work we estimate the clinical penetrance of CTLA-4 insufficiency to be around 67%; however, because genetic analysis could not be performed in all healthy first-degree family members, ascertainment was incomplete. Once symptoms have occurred, the clinical course can be severe and was fatal in 15 affected mutation carriers (16%).
The clinical phenotype was characterized by infections, autoimmunity, and lymphoproliferation, affecting various organ systems. Affected mutation carriers have an increased risk for malignancies and EBV reactivation, highlighting the importance of monitoring EBVand possibly CMV viral load, especially during immunosuppressive treatment. Cytopenia and enteropathy were the most life-threatening and treatment-resistant manifestations. This is evidenced by the fact that cytopenia was one of the main indications for alloHSCT (7/12) , and half of the deceased affected mutation carriers died after a history of enteropathy and associated complications. Initial symptoms were diverse, emphasizing the importance of raising awareness of this immunodeficiency not only among immunologists but also other specialists, including hematologists, neurologists, gastroenterologists, pathologists, dermatologists, and chest physicians. Because the age of onset in 75% of affected mutation carriers is less than 18 years, CTLA-4 insufficiency should be considered in children with severe immune dysregulation of unknown origin. Also, CTLA-4 insufficiency should be considered in subjects being evaluated for inflammatory bowel disease, CVID, and ALPS.
To diagnose CTLA-4 insufficiency, we recommend sequencing the 4 exons of CTLA4 and then testing the effect of identified mutations on the protein by measuring CTLA-4 expression or CTLA-4-mediated transendocytosis. 22 Both were reduced in all analyzed mutation carriers, but because this is also seen in subjects with mutations in other genes, such as lipopolysaccharide-responsive and beige-like anchor protein (LRBA), 23 these functional tests cannot be used as the only diagnostic tool to screen for CTLA4 mutations. In addition to the clinical presentation, an autosomal dominant family history can hint toward CTLA-4 insufficiency.
The immunologic phenotype revealed perturbed T-and B-cell homeostasis and significantly increased Treg cell percentages within the CD4 1 T-cell compartment. The latter might be a transient or permanent compensatory mechanism of the CTLA-4-deficient immune system to counteract immune activation. Expanded and activated effector T cells can produce a cytokine profile leading to increased Treg cell polarization to counterbalance the accelerated immune activation. Increased double-negative T-cell counts in CTLA4 mutation carriers should prompt investigators to evaluate proposed ALPS diagnostic criteria. 24 We present first insights into targeted therapeutic strategies: of 13 affected mutation carriers treated with CTLA-4-Fc, 11 responded favorably, and especially enteropathy improved. Further clinical studies are necessary to determine the effectiveness and safety of CTLA-4-Fc treatment for individual clinical manifestations. Of 12 affected mutation carriers undergoing alloHSCT, 9 are alive and well 15 ; although long-term survival still has to be determined, alloHSCT should be considered a treatment option in carefully selected affected mutation carriers.
In subjects presenting with immunodeficiency, autoimmunity, and lymphoproliferation with impaired Treg cell development or function, in addition to CTLA-4 insufficiency, also mutations in FOXP3, LRBA, IL2RA, FASL, FAS, PI3K, NFKB1, NFKB2, STAT3, and STAT5B should be considered as a differential diagnosis. 6, 23, [25] [26] [27] [28] [29] [30] [31] [32] Mutations in FOXP3 lead to a loss of Treg cells and cause IPEX syndrome, which is an X-linked condition and characterized by enteropathy, immune dysregulation, and polyendocrinopathy but has an earlier onset and complete penetrance. 25, 32 Immunologic findings in patients with IPEX syndrome include normal lymphocyte counts and immunoglobulin levels in contrast to CTLA-4 insufficiency. In patients with LRBA deficiency, lysosomal CTLA-4 degradation is accelerated, and CTLA-4 trafficking to the cell surface is disturbed, hence the inhibitory function of Treg cells is impaired. 23 Biallelic LRBA mutations most often lead to complete absence of the LRBA protein; affected mutation carriers present with a phenotype very similar to CTLA-4 insufficiency that is characterized by various autoimmune features, lymphoproliferation with dysregulated Treg cell function, and a defect in production of cell homeostasis, 26, 29, 30, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] although with an earlier onset, complete penetrance, and autosomal recessive inheritance. In addition, germline gain-of-function mutations in STAT3 lead to a broad range of autoimmune disorders, such as autoimmune cytopenias and multiorgan autoimmunity (lung, gastrointestinal, hepatic, and endocrine) in combination with an increased susceptibility to infections and a short stature. Furthermore, STAT3 gain-of-function mutations lead to secondary defects in STAT5 and STAT1 phosphorylation and impair the Treg cell compartment. 27, 31 Because our results were collected retrospectively, several limiting factors should be considered: affected mutation carriers were treated and evaluated by different physicians and medical departments worldwide. This can lead to an incomplete picture of the clinical phenotype. Also, data were collected at 1 time point, which often makes it difficult to reconstruct whether symptoms or the immunologic phenotype are due to immunosuppressive treatment or the natural course of this immunodeficiency.
In patients with LRBA deficiency, levels of sIL-2R, a biomarker for T cell-mediated inflammation, decrease on abatacept treatment. 23 In our cohort sIL-2R levels were measured only sporadically; in 1 affected mutation carrier sIL-2R levels decreased during abatacept treatment. Systematic measurement of sIL-2R should be considered in all mutation carriers to determine whether it indicates disease activity. Both affected and unaffected mutation carriers show impaired in vitro CTLA-4 function, indicating the presence of additional factors influencing the clinical phenotype and penetrance, such as environmental, genetic, or epigenetic differences. Ethnicity and origin of mutation carriers could influence age of onset, penetrance, and severity of disease-related symptoms. We cannot assess this because the worldwide distribution in our study is not equal, and the diverse countries of origin varied in diagnostic procedures and standards. In general, there could either be a single modifier or multiple interacting factors influencing the clinical phenotype. The latter could explain the highly variable expressivity of the phenotype.
Another hypothesis suggests an internal threshold within the immune system of CTLA-4-insufficient subjects. Once it is exhausted, immune dysregulation cannot be contained by the organism, and subjects experience symptoms; this could explain why healthy mutation carriers can experience life-threatening symptoms late in life (eg, patient B.II.3 had hemophagocytic lymphohistiocytosis and Hodgkin lymphoma at the age of 50 years). These cases teach us to carefully monitor all firstdegree relatives for CTLA-4-associated disease activity while the search for modifying factors in CTLA-4 insufficiency continues.
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Clinical implications: This large cohort of affected CTLA4 mutation carriers provides first insights into different possible treatment options and presents available clinical information on treatment response and survival. With this knowledge, affected mutation carriers will benefit from individualized management.
